Ezetrol Post-Marketing Study

NCT00753883 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-09-17

No results posted yet for this study

Summary

To compare the lipid lowering efficacy of adding ezetimibe to statin vs. statin alone.

Conditions

Interventions

DRUG

simvastatin

simvastatin 20 mg/QD for 6 Weeks.

DRUG

Ezetimibe

Ezetimibe 10 mg/QD for 8 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-05-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00753883 on ClinicalTrials.gov